Document ID: chunk:federal_register_of_legislation:F2024L01542:front:0:p2
Version: federal_register_of_legislation:F2024L01542
Segment Type: other
Provision Reference: 
Character Range: 3111–4211

(q) iloprost;
             (r) infliximab;
             (s) ivacaftor;
             (t) lenalidomide;
             (u) lumacaftor with ivacaftor;
             (v) macitentan;
             (w) mepolizumab;
             (x) midostaurin;
             (y) nusinersen;
             (z) omalizumab;
             (aa) onasemnogene abeparvovec;
             (bb) pasireotide;
             (cc) patisiran;
             (dd) pegcetacoplan;
             (ee) pegvisomant;
             (ff) pomalidomide;
             (gg) ravulizumab;
             (hh) riociguat;
             (ii) risdiplam;
             (jj) romiplostim;
             (kk) selexipag;
             (ll) sildenafil;
             (mm) tadalafil;
             (nn) teduglutide;
             (oo) tezacaftor with ivacaftor and ivacaftor;
             (pp) tocilizumab;
             (qq) ustekinumab;
             (rr) vedolizumab.
 1.                    At the end of Part 6
     add:

         Division 3—Provisions relating to the National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (December Update) Instrument 2024